Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3b) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC).
9-ING-41;Gemcitabine;Nab-Paclitaxel
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3b) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC). ### Output: 9-ING-41;Gemcitabine;Nab-Paclitaxel